EPISODE · Jan 29, 2025 · 12 MIN
Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics
from The EIC Scaling Club Podcast on European Deep Tech · host EIC Scaling Club
In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.
What this episode covers
In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.
NOW PLAYING
Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.